Method for biomarker and drug-target discovery for prostate cancer diagnosis and treatment as well as biomarker assays determined therewith

Method for biomarker and drug-target discovery for prostate cancer diagnosis and treatment as well as biomarker assays determined therewith

  • CN 102,027,373 A
  • Filed: 05/12/2009
  • Published: 04/20/2011
  • Est. Priority Date: 05/14/2008
  • Status: Active Application
First Claim
Patent Images

1. establish cancer diagnosis/prognosis biomarker method for measuring, it may further comprise the steps:

  • (a) based on to individual from healthy non-human mammal and from the measurement of proteins/peptides constituent concentration in the sample protein matter group of the tissue sample protein group of suffering from cancer non-human mammal individuality and serum, blood plasma or blood derivatives or blood itself, and be chosen in qualitatively between health and cancer sample protein matter group show the notable difference behavior those as potential candidate albumen matter/peptide biomarker, thereby identify potential candidate albumen matter/peptide biomarker and drug targets;

    (b) randomly, by to individual from healthy non-human mammal and carry out quantitative mass-spectrometer measurement from potential candidate albumen matter biomarker in the sample protein matter group of serum, blood plasma or the blood derivatives of suffering from cancer non-human mammal individuality or blood itself, and be chosen in demonstrate the detectable quantitative difference behavior of mass spectrum between health and cancer sample protein matter group those as candidate albumen matter/peptide biomarker, thereby the potential candidate albumen matter/peptide biomarker that identifies in the step (a) is verified;

    (c) by to from healthy individual human and from the serum of suffering from the cancer individual human, candidate albumen matter biomarker in the sample protein matter group of blood plasma or blood derivatives or blood itself carries out mass-spectrometer measurement and/or based on the mensuration of affinity reagent, and be chosen in demonstrate between health and cancer sample protein matter group mass spectrum detectable and/or based on those of the detectable difference behavior of the mensuration of affinity reagent as the proteins/peptides biomarker, thereby to identify in the step (a) or randomly in the step (b) the candidate albumen matter/peptide biomarker of empirical tests confirm;

    (d) the Statistics Application method find out through confirm single of step (c) or in groups the proteins/peptides biomarker as being used to detect the cancer patient and/or being used for cancer prognosis and/or the signature of patient'"'"'s classification.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×